For more than a decade, the Wnt–β-catenin pathway has been the focus of intense basic
and clinical research in the bone field because of its importance in skeletal development …

Osteoporosis and cardiovascular disease were long viewed as independent of each other.
However, numerous epidemiological studies, which are discussed in the first part of this …

Sclerostin, an osteocyte-derived inhibitor of bone formation, is linked to mineral bone
disorder. In order to validate its potential as a predictor of vascular calcification, we explored …

Patients with chronic kidney disease (CKD) are at increased risk of osteoporosis and
vascular calcification. Bone demineralization and vascular mineralization go often hand in …

Sclerostin is a negative regulator of the Wnt/β‐catenin signaling and is, therefore, an
important inhibitor of bone formation and turnover. Because ectopic vascular calcification …

This study compared the effectiveness of dynamic resistance training (DRT) versus isometric
RT (IRT) on osteogenesis and hormonal mechanisms involved in maintenance …

Background and aim Chronic kidney disease mineral and bone disorder (CKD-MBD) is
associated with increased morbidity and mortality. Several cross-sectional studies …

Background: Sclerostin is an osteocyte hormone that decreases osteoblastogenesis.
Sclerostin may play a key role in osteoporosis and also in vascular calcification (VC). In …

Aims: Renal osteodystrophy occurs in the early stages of chronic kidney disease (CKD) and
progresses during loss of kidney function. Fibroblast growth factor (FGF)-23 and sclerostin …

Sclerostin, a 22-kDa glycoprotein that is mainly secreted by the osteocytes, is a soluble
inhibitor of canonical Wnt signaling. Therefore, when present at increased concentrations, it …